• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Thyroid Cancer - Pipeline Review, H2 2012 Product Image

Thyroid Cancer - Pipeline Review, H2 2012

  • Published: December 2012
  • 198 pages
  • Global Markets Direct

Thyroid Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Thyroid Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thyroid Cancer.
- A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Thyroid Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Thyroid Cancer 9
Thyroid Cancer Therapeutics under Development by Companies 11
Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Thyroid Cancer Therapeutics – Products under Development by Companies 21
Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Thyroid Cancer Therapeutics Development 26
F. Hoffmann-La Roche Ltd. 26
AstraZeneca PLC 27
Daiichi Sankyo Company, Ltd 28
Takeda Pharmaceutical Company Limited 29
Plexxikon Inc. 30
Bio-Path Holdings, Inc. 31
Novartis AG 32
Eisai Co., Ltd. 33
Pfizer Inc. 34
Exelixis, Inc. 35
Bayer AG 36
OXiGENE, Inc. 37
Azaya Therapeutics, Inc. 38
Vascular Biogenics Ltd. 39
Globeimmune, Inc. 40
Genelux Corporation 41
Trophogen, Inc. 42
Thyroid Cancer – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 50
lenvatinib - Drug Profile 50
motesanib diphosphate - Drug Profile 52
sorafenib tosylate - Drug Profile 54
axitinib - Drug Profile 56
vandetanib - Drug Profile 58
vandetanib - Drug Profile 60
panobinostat - Drug Profile 62
docetaxel - Drug Profile 65
vemurafenib - Drug Profile 67
cabozantinib - Drug Profile 70
cabozantinib - Drug Profile 72
VB-111 - Drug Profile 74
BP-100-1.02 - Drug Profile 76
CP-4033 - Drug Profile 77
Gleevec + Dacarbazine + Xeloda - Drug Profile 78
tanespimycin - Drug Profile 80
vandetanib - Drug Profile 81
gefitinib - Drug Profile 83
GI-6207 - Drug Profile 84
pazopanib hydrochloride - Drug Profile 85
romidepsin - Drug Profile 86
selumetinib - Drug Profile 88
sorafenib tosylate - Drug Profile 89
sorafenib tosylate - Drug Profile 90
Boronophenylalanine-Fructose Complex - Drug Profile 93
imatinib - Drug Profile 95
PLX-3397 - Drug Profile 96
lithium carbonate - Drug Profile 98
Temsirolimus + Sorafenib - Drug Profile 99
Valproic Acid - Drug Profile 100
lenalidomide - Drug Profile 101
thalidomide - Drug Profile 102
Hydroxyurea + Fluorouracil + Paclitaxel + G-CSF + Radiation Therapy - Drug Profile 103
romidepsin - Drug Profile 105
Almita + Paclitaxel - Drug Profile 106
fosbretabulin tromethamine - Drug Profile 107
Zybrestat + Carboplatin + Paclitaxel - Drug Profile 109
cediranib maleate - Drug Profile 111
sorafenib tosylate - Drug Profile 111
valproic acid - Drug Profile 113
Aflibercept - Drug Profile 114
Everolimus + Sorafenib - Drug Profile 116
fostamatinib disodium - Drug Profile 117
sunitinib malate - Drug Profile 118
lithium carbonate - Drug Profile 120
cisplatin - Drug Profile 121
Paclitaxel + Pazopanib - Drug Profile 123
Cisplatin + EPC2407 - Drug Profile 125
sunitinib malate - Drug Profile 126
Cediranib + Lenalidomide - Drug Profile 127
CS-7017 + Paclitaxel - Drug Profile 128
Avastin + Doxorubicin - Drug Profile 129
Alimta + Paclitaxel - Drug Profile 130
ETD-5 - Drug Profile 131
Everolimus + SOM230 - Drug Profile 132
Pazopanib + Iodine I 131 - Drug Profile 133
thalidomide - Drug Profile 134
Pazopanib + GSK1120212 - Drug Profile 135
SOM-230 + RAD-001 - Drug Profile 137
pasireotide - Drug Profile 138
TSH Analog - Drug Profile 139
pioglitazone - Drug Profile 140
Reversine - Drug Profile 141
PLX-4720 - Drug Profile 142
withanolide - Drug Profile 143
Thyroid Cancer Therapeutics – Drug Profile Updates 144
Thyroid Cancer Therapeutics – Discontinued Products 182
Thyroid Cancer Therapeutics - Dormant Products 183
Thyroid Cancer – Product Development Milestones 186
Featured News & Press Releases 186
Appendix 192
Methodology 192
Coverage 192
Secondary Research 192
Primary Research 192
Expert Panel Validation 192
Contact Us 193
Disclaimer 193

List of Tables
Number of Products Under Development for Thyroid Cancer, H2 2012 14
Products under Development for Thyroid Cancer – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Development by Companies, H2 2012 (Contd..1) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 30
F. Hoffmann-La Roche Ltd., H2 2012 31
AstraZeneca PLC, H2 2012 32
Daiichi Sankyo Company, Ltd, H2 2012 33
Takeda Pharmaceutical Company Limited, H2 2012 34
Plexxikon Inc., H2 2012 35
Bio-Path Holdings, Inc., H2 2012 36
Novartis AG, H2 2012 37
Eisai Co., Ltd., H2 2012 38
Pfizer Inc., H2 2012 39
Exelixis, Inc., H2 2012 40
Bayer AG, H2 2012 41
OXiGENE, Inc., H2 2012 42
Azaya Therapeutics, Inc., H2 2012 43
Vascular Biogenics Ltd., H2 2012 44
Globeimmune, Inc., H2 2012 45
Genelux Corporation, H2 2012 46
Trophogen, Inc., H2 2012 47
Assessment by Monotherapy Products, H2 2012 48
Assessment by Combination Products, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 54
Thyroid Cancer Therapeutics – Drug Profile Updates 149
Thyroid Cancer Therapeutics – Discontinued Products 187
Thyroid Cancer Therapeutics – Dormant Products 188
Thyroid Cancer Therapeutics – Dormant Products (Contd..1) 189
Thyroid Cancer Therapeutics – Dormant Products (Contd..2) 190

List of Figures
Number of Products under Development for Thyroid Cancer, H2 2012 14
Products under Development for Thyroid Cancer – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 48
Assessment by Combination Products, H2 2012 49
Assessment by Route of Administration, H2 2012 50
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Molecule Type, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 53

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos